Cargando…

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

PURPOSE: This multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment of advanced hepatocellular carcinoma (aHCC). METHODS: Patients with histologically confirmed aHCC wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Qian, Han, Chun, Ye, Sisi, Li, Juan, Shao, Guoliang, Bai, Yuxian, Xu, Aibing, Sun, Meili, Wang, Wei, Wu, Jian, Huang, Ming, Song, Lijie, Huang, Luke, Liu, Ting, Liu, Wei, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Michelle, Bai, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627805/ https://www.ncbi.nlm.nih.gov/pubmed/37942328 http://dx.doi.org/10.3389/fimmu.2023.1238667

Ejemplares similares

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
por: Pang, Xinghua, et al.
Publicado: (2023)

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
por: Chen, Peng-Yu, et al.
Publicado: (2023)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
por: Han, Chun, et al.
Publicado: (2021)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
por: Xu, Jianming, et al.
Publicado: (2020)

Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report
por: Peng, Jieqiong, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
por: Li, Xingzhi, et al.
Publicado: (2023)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023)

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
por: Wei, Fuqun, et al.
Publicado: (2021)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
por: Sun, Qi, et al.
Publicado: (2022)

08.08.08, czyli najbardziej zagadkowy dzień roku
Publicado: (2008)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
por: Xu, Rui-Hua, et al.
Publicado: (2017)

Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
por: Liu, Chengxin, et al.
Publicado: (2023)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
por: Guo, Jun, et al.
Publicado: (2021)

HLA-A and HLA-B genes are involved in the pathogenesis of IBS
por: Liang, Huiping, et al.
Publicado: (2023)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
por: Taylor, Matthew H., et al.
Publicado: (2020)

The protective effects of electroacupuncture on intestinal barrier lesions in IBS and UC model
por: Liu, Shuqing, et al.
Publicado: (2023)

Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study
por: Chen, Yen-Yang, et al.
Publicado: (2021)

High-resolution mapping of a major and consensus quantitative trait locus for oil content to a ~ 0.8-Mb region on chromosome A08 in peanut (Arachis hypogaea L.)
por: Liu, Nian, et al.
Publicado: (2019)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT
por: Ye, Jianwen, et al.
Publicado: (2021)

HCS08 unleashed: designer's guide to the HCS08 microcontrollers
por: Pereira, Fabio
Publicado: (2009)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Advances in the study of HLA class Ib in maternal-fetal immune tolerance
por: Yang, Yiran, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
por: Li, Wei, et al.
Publicado: (2023)

Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
por: Bai, Shilei, et al.
Publicado: (2022)

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
por: Hou, Wei, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
por: Zhu, Yun, et al.
Publicado: (2021)

iMovie '08 & iDVD '08 for Mac OS X
por: Carlson, Jeff
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_s98764rviqabl02l7k2912qh32